個(gè)人簡(jiǎn)介：
? ? 中山大學(xué)附屬第七醫(yī)院科研中心研究員,，博士生導(dǎo)師,，中山大學(xué)高層次人才計(jì)劃中青年杰出人才，廣東省“珠江計(jì)劃” 領(lǐng)軍人才,，深圳市衛(wèi)生健康B類人才,。2013年獲得柏林洪堡大學(xué)細(xì)胞生物學(xué)博士學(xué)位（導(dǎo)師Walter Birchmeier院士），2014-2020年先后在德國(guó)MDC分子醫(yī)學(xué)中心（合作導(dǎo)師Walter Birchmeier院士）和英國(guó)Francis Crick研究所（合作導(dǎo)師Axel Behrens院士）進(jìn)行博士后研究,，2021-2023年在英國(guó)倫敦腫瘤研究所（ICR）任職終身高級(jí)科學(xué)家（Staff Scientist）,。2023年4月通過(guò)中山大學(xué)高層次人才計(jì)劃加入中山大學(xué)附屬第七醫(yī)院,。以第一/共同第一作者在Nature, EMBO J, Cancer Res及Cell Mol Life Sci等期刊發(fā)表多篇研究論文。主持國(guó)家自然科學(xué)基金和深圳市醫(yī)學(xué)研究專項(xiàng)資金等多個(gè)項(xiàng)目,。
?
主要研究方向:
1.?腫瘤細(xì)胞譜系異質(zhì)性的時(shí)空演化及其調(diào)控機(jī)機(jī)制：
（1）腫瘤細(xì)胞譜系異質(zhì)性在耐藥和轉(zhuǎn)移過(guò)程中的時(shí)空演化,；
（2）腫瘤細(xì)胞可塑性和干性對(duì)腫瘤譜系異質(zhì)性的調(diào)控。
2.?腫瘤微環(huán)境（如腫瘤相關(guān)成纖維細(xì)胞和神經(jīng)細(xì)胞）的空間組織模式和功能解析,。
3. 小鼠腫瘤模型和腫瘤類器官模型建立和優(yōu)化,。
?
主要科研論文：
1.?Lan L, Evan T, Li H, Hussain A, Ruiz EJ, Zaw Thin M, Ferreira RMM, Ps H, Riising EM, Zen Y, Almagro J, Ng KW, Soro-Barrio P, Nelson J, Koifman G, Carvalho J, Nye EL, He Y, Zhang C,? ? ? ? ? ? ?Sadanandam A, Behrens A. GREM1 is required to maintain cellular heterogeneity in pancreatic cancer. Nature?2022;607(7917):163-168.
2.?Chen H, Li Y, Li H, Chen X, Fu H, Mao D, Chen W, Lan L, Wang C, Hu K, Li J, Zhu C, Evans I, Cheung E, Lu D, He Y, Behrens A, Yin D, Zhang C. NBS1 lactylation is required for efficient DNA? ? ?repair and chemotherapy resistance. Nature. 2024;631(8021):663-669.
3.?Lan L, Behrens A. Are there Specific Cancer Stem Cell Markers? Cancer Res?2023;83(2):170-172.
4.?Li H#, Wang C#, Lan L#, Yan L#, Li W, Evans I, Ruiz EJ, Su Q, Zhao G, Wu W, Zhang H, Zhou Z, Hu Z, Chen W, Oliveira JM, Behrens A, Reis RL, Zhang C. METTL3 promotes oxaliplatin? ? ? ? ? ? ? resistance of gastric cancer CD133+?stem cells by promoting PARP1 mRNA stability. Cell Mol Life Sci 2022;79(3):135. #Co-first author.
5.?Ruiz EJ, Lan L, Diefenbacher ME, Riising EM, Da Costa C, Chakraborty A, Hoeck JD, Spencer-Dene B, Kelly G, David JP, Nye E, Downward J, Behrens A. JunD, not c-Jun, is the AP-1 transcription factor required for Ras-induced lung cancer. JCI Insight?2021;6(13):e124985.
6.?Li H#, Wang C#, Lan L#, Wu W, Evans I, Ruiz EJ, Yan L, Zhou Z, Oliveira JM, Reis RL, Hu Z, Chen W, Behrens A, He Y, Zhang C. PARP1 Inhibitor Combined With Oxaliplatin Efficiently Suppresses Oxaliplatin Resistance in Gastric Cancer-Derived Organoids via Homologous Recombination and the Base Excision Repair Pathway. Front Cell Dev Biol?2021; 9:719192. #Co-first author.
7.?Li H#, Wang C#, Lan L#, Behrens A, Tomaschko M, Ruiz J, Su Q, Zhao G, Yuan C, Xiao X, Li B, Yan L, Wu W, Li W, Chen J, He Y, Zhang C. High expression of vinculin predicts poor prognosis and distant metastasis and associates with influencing tumor-associated NK cell infiltration and epithelial-mesenchymal transition in gastric cancer. Aging (Albany NY)?2021;13(4):5197-5225.?#Co-first author.
8.?Lan L, Holland JD, Qi J, Grosskopf S, Rademann J, Vogel R, Gy?rffy B, Wulf-Goldenberg A, Birchmeier W. Shp2 signaling suppresses senescence in PyMT-induced mammary gland cancer in mice. EMBO J?2015;34(11):1493-508.
9.?Lan L, Han H, Zuo H, Chen Z, Du Y, Zhao W, Gu J, Zhang Z. Upregulation of myosin Va by Snail is involved in cancer cell migration and metastasis. Int J Cancer?2010;126(1):53-64.
10.?Lan L, Zhao F, Wang Y, Zeng H. The mechanism of apoptosis induced by a novel thioredoxin reductase inhibitor in A549 cells: possible involvement of nuclear factor-kB-dependent pathway. Euro J Pharmacol?2007;555(2-3):83-92.
?
個(gè)人郵箱:
lanlx5@mail.sysu.edu.cn